Curated News
By: NewsRamp Editorial Staff
February 24, 2026

Helix BioPharma Unveils Promising New Cancer Target Data at Global ADC Conference

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • Helix BioPharma's CEACAM6-targeted ADC technology offers a potential competitive edge in oncology by selectively attacking hard-to-treat cancers with minimal side effects.
  • Helix BioPharma's ADC program uses proprietary VHH nanobodies to bind selectively to CEACAM6, delivering potent payloads directly to cancer cells while minimizing off-target effects.
  • This targeted therapy could make tomorrow better by providing more effective, less toxic treatments for hard-to-treat cancers, improving patient outcomes and quality of life.
  • Helix BioPharma presented data on camelid-derived nanobodies that selectively target CEACAM6, an emerging cancer marker with broad potential across multiple tumor types.

Impact - Why it Matters

This news matters because it highlights a significant advancement in targeted cancer therapy. Antibody-drug conjugates (ADCs) represent one of the most promising frontiers in oncology, offering the potential to deliver powerful chemotherapy agents directly to cancer cells while sparing healthy tissue, thereby reducing debilitating side effects. CEACAM6, the target discussed by Helix, is expressed in a broad range of aggressive epithelial cancers, including lung, pancreatic, and colorectal cancers, which are often difficult to treat with conventional methods. The development of a highly selective therapy for this target could lead to new, more effective treatment options for patients with limited alternatives, potentially improving survival rates and quality of life. Furthermore, Helix's use of VHH/nanobody technology represents a next-generation approach that could offer advantages in tumor penetration and manufacturing over traditional antibodies, accelerating the pace of innovation in the fight against cancer.

Summary

Helix BioPharma Corp., a clinical-stage oncology company trading on the TSX, OTC PINK, and Frankfurt exchanges, has announced a significant presentation at the prestigious 16th Annual World ADC London conference. The company's Director of ADC Discovery, Dr. Jonathan Davis, delivered a presentation titled "Next-Generation ADCs: Unlocking the Potential of CEACAM6-Directed Targeted Therapies," highlighting their proprietary antibody-drug conjugate (ADC) program. This event, a leading global forum for ADC research and development, provided a platform for Helix to showcase its growing leadership in innovative cancer therapies, with Dr. Davis's selection underscoring the company's expertise in this cutting-edge field.

The core of the presentation focused on CEACAM6, a highly attractive therapeutic target due to its elevated expression in many epithelial cancers and association with poor clinical outcomes. Dr. Davis presented data on Helix's proprietary anti-CEACAM6 VHH, a single-domain antibody fragment or "nanobody" derived from camelid antibodies, which demonstrated a highly selective tumor-binding profile. This specificity is crucial for developing next-generation ADCs designed to deliver potent therapeutic payloads directly to cancer cells while minimizing harmful off-target effects in healthy tissues. The research builds upon the clinical foundation of Helix's lead candidate, Tumor Defense Breaker™ L-DOS47, which has shown favorable safety and encouraging activity in Phase I/II studies for non-small cell lung cancer (NSCLC).

Dr. Davis emphasized that CEACAM6 represents a compelling and underexploited target with broad potential across multiple hard-to-treat cancers. The presentation generated strong interest among conference participants, reflecting the growing recognition of CEACAM6 as an important emerging target in oncology. A copy of the presentation is available on the Company's website. Helix's broader pipeline also includes pre-IND candidates LEUMUNA™, an oral immune checkpoint modulator, and GEMCEDA™, an oral gemcitabine prodrug. The original news release can be viewed on www.newmediawire.com, and more information about the World ADC London conference, which brings together over 700 industry stakeholders, is available at its official website.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Helix BioPharma Unveils Promising New Cancer Target Data at Global ADC Conference

blockchain registration record for this content.